Seeking Alpha
 

TearLab Corporation (TEAR)

- NASDAQ
  • Mon, Jan. 26, 12:46 PM
    | 6 Comments
  • Aug. 8, 2014, 3:49 PM
    • First the good news:
    • Tekmira (TKMR +38.1%) on a massive 25M share turnover; Raptor Pharmaceuticals (RPTP +28.2%) on a 4x surge in volume; Clovis Oncology (CLVS +11.6%) on 50% higher volume; RadNet (RDNT +20.4%) on 2x higher volume and Relypsa (RLYP +15%) on 2x higher volume.
    • Now the bad news:
    • TearLab (TEAR -21.2%) on 4x higher volume; Masimo (MASI -10.6%) on 3x higher volume; Volcano (VOLC -19.9%) on a 12x surge in volume and Hanger (HGR -24.9%) on a 16x surge in volume.
    | 1 Comment
  • Apr. 21, 2014, 12:46 PM
    | 5 Comments
  • Jan. 29, 2014, 12:46 PM
    | 1 Comment
  • Aug. 14, 2013, 9:13 AM
    | 1 Comment
  • Aug. 1, 2013, 12:57 PM
    • Tearlab (TEAR -5.5%) slips on a negative article out of Streetsweeper today.
    • The short seller calls TEAR "a bleeding firm with a long history of failure." adding that many doctors are no longer using its machine for diagnostic eye testing, citing inaccuracies in testing data and calling it an outright lemon.
    | Comment!
  • Jul. 25, 2013, 9:39 AM
    TearLab (TEAR +7.8%) soars out of the gate and is now up 25% since Monday. The company priced its public offering at $13.50/ share for gross proceeds of $35.1M. Cramer says the stock is on a roll and although he thinks it may be time to take some profits, he recommends leaving at least half on the table.
    | Comment!
  • Jun. 3, 2013, 9:13 AM
    Premarket gainers: ASI +21%. TEAR +11%. PPHM +12%. OSH +9%. CLP +7%. MTL +6%. SODA +5%. INFY +5%.
    Losers: AFFY -27%. INFI -16%. NBG -13%. SNTA -12%.
    | Comment!
  • May. 14, 2013, 12:45 PM
    Midday top 10 gainers: PDII +31%. UNTK +22%. ALIM +19%. SODA +15%. CHLN +15%. TEAR +14%. ESI +14%. ECTY +14%. BVSN +12%. RVLT 12%.
    Midday top 10 losers: TELOZ -28%. OPXA -19%. SED -16%. STXS -14%. FMAR -13%. VELT -12%. TSRE -12%. TRMD -11%. CCCL -10%. PT -10%.
    | Comment!
  • May. 14, 2013, 10:23 AM
    TearLab (TEAR +10.6%) ramps higher this morning after reporting Q1 sales that topped the Street's $2.19M estimate. Net revenues soared 486% from the same period last year, and an increase of 54% sequentially from the previous quarter. A total of 388 orders for its TearLab Osmolarity systems were booked in Q1. Net losses for the quarter were $9.1M, including approximately $6.6M in non-cash expense related to the revaluation of warrants issued in June 2011. As of March 31, the company had $12.3M remaining in cash.
    | Comment!
  • Aug. 29, 2012, 9:16 AM
    TearLab (TEAR) +6.2% premarket after Canaccord Genuity initiates coverage with a Buy rating a $6 price target, noting the company offers the first point of care instrument that can quantitatively measure and diagnose dry eye disease. The firm says U.S. market potential includes 50,000 eye specialists who see on average six dry eye patients per day, equaling a $1.8B opportunity.
    | Comment!
  • Aug. 29, 2012, 9:10 AM
    Premarket gainers: JOSB +14%. TEAR +8%. MCP +6%. TFM +5%.
    Losers: ARQL -26%. WCRX -22%. DY -17%. JASO -9%. FRO -8%.
    | Comment!
TEAR vs. ETF Alternatives
Company Description
TearLab Corp is an in-vitro diagnostic company. It commercializes a proprietary tear testing platform that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film.